9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The risk of complications of endoscopic procedures in patients with liver cirrhosis

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Endoscopy methods involve diagnostics as well as therapy. Endoscopic techniques have a small but definite incidence of complication, so endoscopy should not be performed routinely but only on the basis of indication. The typical endoscopic procedures used in diagnostics and therapy of liver cirrhosis are endoscopy of upper and lower gastrointestinal tract. Other techniques are less common. Significance of endoscopy procedures increases in case of chronic progressive liver diseases, independently of etiology, where changes in gastrointestinal tract are observed in 87% of patients.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis.

          Hepatocellular carcinoma (HCC) is increasing in incidence in many countries, and is the most common cause of death in patients with cirrhosis. With regular surveillance, small early HCC lesions can be identified. An algorithm has been developed that allows for diagnosis of these lesions. Very early HCC lesions have high cure rates with appropriate treatment. If all these factors are in place most HCCs can be cured.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

            Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombopoiesis. We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis. Seventy-four patients with HCV-related cirrhosis and platelet counts of 20,000 to less than 70,000 per cubic millimeter were randomly assigned to receive eltrombopag (30, 50, or 75 mg daily) or placebo daily for 4 weeks. The primary end point was a platelet count of 100,000 per cubic millimeter or more at week 4. Peginterferon and ribavirin could then be initiated, with continuation of eltrombopag or placebo for 12 additional weeks. At week 4, platelet counts were increased to 100,000 per cubic millimeter or more in a dose-dependent manner among patients for whom these data were available: in 0 of the 17 patients receiving placebo, in 9 of 12 (75%) receiving 30 mg of eltrombopag, in 15 of 19 (79%) receiving 50 mg of eltrombopag, and in 20 of 21 (95%) receiving 75 mg of eltrombopag (P<0.001). Antiviral therapy was initiated in 49 patients (in 4 of 18 patients receiving placebo, 10 of 14 receiving 30 mg of eltrombopag, 14 of 19 receiving 50 mg of eltrombopag, and 21 of 23 receiving 75 mg of eltrombopag) while the administration of eltrombopag or placebo was continued. Twelve weeks of antiviral therapy, with concurrent receipt of eltrombopag or placebo, were completed by 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, and 75 mg of eltrombopag, respectively, and by 6% of patients in the placebo group. The most common adverse event during the initial 4 weeks was headache; thereafter, the adverse events were those expected with interferon-based therapy. Eltrombopag therapy increases platelet counts in patients with thrombocytopenia due to HCV-related cirrhosis, thereby permitting the initiation of antiviral therapy. (ClinicalTrials.gov number, NCT00110799.) 2007 Massachusetts Medical Society
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Infection, coagulation, and variceal bleeding in cirrhosis.

                Bookmark

                Author and article information

                Journal
                Clin Exp Hepatol
                Clin Exp Hepatol
                CEH
                Clinical and Experimental Hepatology
                Termedia Publishing House
                2392-1099
                2449-8238
                25 September 2017
                September 2017
                : 3
                : 3
                : 135-140
                Affiliations
                Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Poland
                I Department of Infectious Diseases, Regional Specialistic Hospital, Wroclaw, Poland
                Author notes
                Address for correspondence Krzysztof Simon, Department of Infectious Diseases and Hepatology, Wroclaw Medical University, 5 Koszarowa St., 51-149 Wroclaw, Poland. e-mail: krzysimon@ 123456gmail.com
                Article
                30671
                10.5114/ceh.2017.70284
                5649487
                adfa7819-5ce3-4a93-a5d8-20fb8ae56052
                Copyright: © 2017 Clinical and Experimental Hepatology

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

                History
                : 03 June 2017
                : 22 June 2017
                Categories
                Review Paper

                liver cirrhosis,esophagogastroduodenoscopy,colonoscopy,portal hypertension

                Comments

                Comment on this article